Skip to content
2000
  1. Home
  2. A-Z Publications
  3. CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders)
  4. Volume 23, Issue 1
  5. Article
Volume 23, Issue 1
  • ISSN: 1871-5273
  • E-ISSN: 1996-3181

Abstract

Anxiety and depression are prevalent mental disorders around the world. The etiology of both diseases is multifactorial, involving biological and psychological issues. The COVID-19 pandemic settled in 2020 and culminated in several changes in the routine of individuals around the world, affecting mental health. People infected with COVID-19 are at greater risk of developing anxiety and depression, and individuals previously affected by these disorders have worsened the condition. In addition, individuals diagnosed with anxiety or depression before being affected by COVID-19 developed the severe illness at higher rates than individuals without mental disorders. This harmful cycle involves several mechanisms, including systemic hyper-inflammation and neuroinflammation. Furthermore, the context of the pandemic and some previous psychosocial factors can aggravate or trigger anxiety and depression. Disorders are also risks for a more severe picture of COVID-19. This review discusses research on a scientific basis, which brings evidence on biopsychosocial factors from COVID-19 and the context of the pandemic involved in anxiety and depression disorders.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/1871527322666230210100048
2024-01-01
2025-01-07

  • From This Site

    /content/journals/cnsnddt/10.2174/1871527322666230210100048
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. FerrareseC. SilaniV. PrioriA. An Italian multicenter retrospective-prospective observational study on neurological manifestations of COVID-19 (NEUROCOVID).Neurol. Sci.20204161355135910.1007/s10072‑020‑04450‑132430621
     [Google Scholar]
  2. EspíndolaO.M. GomesY.C.P. BrandãoC.O. Inflammatory cytokine patterns associated with neurological diseases in coronavirus disease 2019.Ann. Neurol.20218951041104510.1002/ana.2604133547819
     [Google Scholar]
  3. WeiN. HuangB. LuS. Efficacy of internet-based integrated intervention on depression and anxiety symptoms in patients with COVID-19.J. Zhejiang Univ. Sci. B202021540040410.1631/jzus.B201001332425006
     [Google Scholar]
  4. World Health Organization. Depression and other common mental disorders: global health estimates Geneva: World Health Organization 2017. Available from: https://apps.who.int/iris/handle/10665/254610https://apps.who.int/iris/handle/10665/254610 (Accessed on: 16th April 2022).
  5. MeiQ. WangF. BryantA. WeiL. YuanX. LiJ. Mental health problems among COVID ‐19 survivors in Wuhan, China.World Psychiatry202120113914010.1002/wps.2082933432745
     [Google Scholar]
  6. Rossi FerrarioS. PanzeriA. CeruttiP. SaccoD. The psychological experience and intervention in post-acute covid-19 inpatients.Neuropsychiatr. Dis. Treat.20211741342210.2147/NDT.S28355833603379
     [Google Scholar]
  7. B.C. UB, Pokharel S, Munikar S, Wagle CN, Adhikary P, Shahi BB, et al. Anxiety and depression among people living in quarantine centers during COVID-19 pandemic: A mixed method study from western Nepal.PLoS One2021167e025412610.1371/journal.pone.0254126
     [Google Scholar]
  8. HernándezV.S. ZetterM.A. GuerraE.C. ACE2 expression in rat brain: Implications for COVID-19 associated neurological manifestations.Exp. Neurol.202134511383710.1016/j.expneurol.2021.11383734400158
     [Google Scholar]
  9. HuangC. WangY. LiX. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet20203951022349750610.1016/S0140‑6736(20)30183‑531986264
     [Google Scholar]
  10. Conde CardonaG. Quintana PájaroL.D. Quintero MarzolaI.D. Ramos VillegasY. Moscote SalazarL.R. Neurotropism of SARS-CoV 2: Mechanisms and manifestations.J. Neurol. Sci.202041211682410.1016/j.jns.2020.11682432299010
     [Google Scholar]
  11. MaoL. JinH. WangM. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in wuhan, china.JAMA Neurol.202077668369010.1001/jamaneurol.2020.112732275288
     [Google Scholar]
  12. LiguoriC. PierantozziM. SpanettaM. Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection.Brain Behav. Immun.202088111610.1016/j.bbi.2020.05.03732416289
     [Google Scholar]
  13. HelmsJ. KremerS. MerdjiH. Neurologic features in severe SARS-CoV-2 infection.N. Engl. J. Med.2020382232268227010.1056/NEJMc200859732294339
     [Google Scholar]
  14. CacciatoreM. RaggiA. PilottoA. Neurological and mental health symptoms associated with post-covid-19 disability in a sample of patients discharged from a COVID-19 Ward: A secondary analysis.Int. J. Environ. Res. Public Health2022197424210.3390/ijerph1907424235409924
     [Google Scholar]
  15. LauK.K. YuW.C. ChuC.M. LauS.T. ShengB. YuenK.Y. Possible central nervous system infection by SARS coronavirus.Emerg. Infect. Dis.200410234234410.3201/eid1002.03063815030709
     [Google Scholar]
  16. HungE.C.W. ChimS.S.C. ChanP.K.S. Detection of SARS coronavirus RNA in the cerebrospinal fluid of a patient with severe acute respiratory syndrome.Clin. Chem.200349122108210910.1373/clinchem.2003.02543714633896
     [Google Scholar]
  17. SalekiK. BanazadehM. SaghazadehA. RezaeiN. The involvement of the central nervous system in patients with COVID-19.Rev. Neurosci.202031445345610.1515/revneuro‑2020‑002632463395
     [Google Scholar]
  18. YangA.C. KernF. LosadaP.M. Publisher Correction: Dysregulation of brain and choroid plexus cell types in severe COVID-19.Nature20215987882E4E410.1038/s41586‑021‑04080‑334625744
     [Google Scholar]
  19. PrakashA. SinghH. SarmaP. nCoV-2019 infection induced neurological outcome and manifestation, linking its historical ancestor SARS-CoV and MERS-CoV: a systematic review and meta-analysis.Sci. Rep.20211111288810.1038/s41598‑021‑92188‑x34145351
     [Google Scholar]
  20. FerrariM.F.R. RaizadaM.K. Fior-ChadiD.R. Nicotine modulates the renin-angiotensin system of cultured neurons and glial cells from cardiovascular brain areas of Wistar Kyoto and spontaneously hypertensive rats.J. Mol. Neurosci.200733328429310.1007/s12031‑007‑9006‑x17952638
     [Google Scholar]
  21. XiaH. LazartiguesE. Angiotensin-converting enzyme 2 in the brain: properties and future directions.J. Neurochem.200810761482149410.1111/j.1471‑4159.2008.05723.x19014390
     [Google Scholar]
  22. GowrisankarY.V. ClarkM.A. Angiotensin II regulation of angiotensin-converting enzymes in spontaneously hypertensive rat primary astrocyte cultures.J. Neurochem.20161381748510.1111/jnc.1364127085714
     [Google Scholar]
  23. ChanP.K.S. ToK.F. LoA.W.I. Persistent infection of SARS coronavirus in colonic cells in vitro.J. Med. Virol.20047411710.1002/jmv.2013815258961
     [Google Scholar]
  24. ZhouP. YangX.L. WangX.G. A pneumonia outbreak associated with a new coronavirus of probable bat origin.Nature2020579779827027310.1038/s41586‑020‑2012‑732015507
     [Google Scholar]
  25. HoffmannM. Kleine-WeberH. SchroederS. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.Cell20201812271280.e810.1016/j.cell.2020.02.05232142651
     [Google Scholar]
  26. ShullaA. Heald-SargentT. SubramanyaG. ZhaoJ. PerlmanS. GallagherT. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry.J. Virol.201185287388210.1128/JVI.02062‑1021068237
     [Google Scholar]
  27. MatsuyamaS. NagataN. ShiratoK. KawaseM. TakedaM. TaguchiF. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2.J. Virol.20108424126581266410.1128/JVI.01542‑1020926566
     [Google Scholar]
  28. GlowackaI. BertramS. MüllerM.A. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response.J. Virol.20118594122413410.1128/JVI.02232‑1021325420
     [Google Scholar]
  29. BullenC.K. HogbergH.T. Bahadirli-TalbottA. Infectability of human BrainSphere neurons suggests neurotropism of SARS-CoV-2.Altern. Anim. Exp.202037466567110.14573/altex.200611132591839
     [Google Scholar]
  30. FilatovA. SharmaP. HindiF. EspinosaP.S. Neurological complications of coronavirus disease (COVID-19): Encephalopathy.Cureus2020123e735210.7759/cureus.7352
     [Google Scholar]
  31. NajjarS. NajjarA. ChongD.J. Central nervous system complications associated with SARS-CoV-2 infection: integrative concepts of pathophysiology and case reports.J. Neuroinflammation202017123110.1186/s12974‑020‑01896‑032758257
     [Google Scholar]
  32. BrisonE. JacomyH. DesforgesM. TalbotP.J. Glutamate excitotoxicity is involved in the induction of paralysis in mice after infection by a human coronavirus with a single point mutation in its spike protein.J. Virol.20118523124641247310.1128/JVI.05576‑1121957311
     [Google Scholar]
  33. BattagelloD.S. DragunasG. KleinM.O. AyubA.L.P. VellosoF.J. CorreaR.G. Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission.Clin. Sci.2020134162137216010.1042/CS2020090432820801
     [Google Scholar]
  34. WangF. KreamR.M. StefanoG.B. Long-term respiratory and neurological sequelae of COVID-19.Med. Sci. Monit.202026e92899610.12659/MSM.92899633177481
     [Google Scholar]
  35. KempurajD. SelvakumarG.P. AhmedM.E. COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation.Neuroscientist2020265-640241410.1177/107385842094147632684080
     [Google Scholar]
  36. RaonyÍ. de FigueiredoC.S. PandolfoP. Giestal-de-AraujoE. Oliveira-Silva BomfimP. SavinoW. Psycho-neuroendocrine-immune interactions in covid-19: Potential impacts on mental health.Front. Immunol.202011117010.3389/fimmu.2020.0117032574266
     [Google Scholar]
  37. BorscheM. ReichelD. FellbrichA. Persistent cognitive impairment associated with cerebrospinal fluid anti-SARS-CoV-2 antibodies six months after mild COVID-19.Neurol Res Pract2021313410.1186/s42466‑021‑00135‑y34148546
     [Google Scholar]
  38. KamelW.A. IsmailI.I. IbrahimM. Al-HashelJ.Y. Unexplained worsening of parkinsonian symptoms in a patient with advanced Parkinson’s disease as the sole initial presentation of COVID-19 infection: a case report.Egypt. J. Neurol. Psychiat. Neurosurg.20215716010.1186/s41983‑021‑00314‑334025113
     [Google Scholar]
  39. LiW. MooreM.J. VasilievaN. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.Nature2003426696545045410.1038/nature0214514647384
     [Google Scholar]
  40. Jansen van VurenE. SteynS.F. BrinkC.B. MöllerM. ViljoenF.P. HarveyB.H. The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.Biomed. Pharmacother.202113511120010.1016/j.biopha.2020.11120033421734
     [Google Scholar]
  41. Zhang J jin, Dong X, Cao Y yuan, Yuan Y dong, Yang Y bin, Yan Y qin, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China.Allergy20207571730-4110.1111/all.14238
     [Google Scholar]
  42. StrafellaC. CaputoV. TermineA. Investigation of genetic variations of IL6 and IL6R as potential prognostic and pharmacogenetics biomarkers: implications for covid-19 and neuroinflammatory disorders.Life2020101235110.3390/life1012035133339153
     [Google Scholar]
  43. CazzollaA.P. LoveroR. Lo MuzioL. Taste and smell disorders in COVID-19 patients: Role of interleukin-6.ACS Chem. Neurosci.202011172774278110.1021/acschemneuro.0c0044732786309
     [Google Scholar]
  44. TanaC. BentivegnaE. ChoS.J. Long COVID headache.J. Headache Pain20222319310.1186/s10194‑022‑01450‑835915417
     [Google Scholar]
  45. MartellettiP. BentivegnaE. SpuntarelliV. LucianiM. Long-COVID headache.SN Compr. Clin. Med.2021381704170610.1007/s42399‑021‑00964‑734036244
     [Google Scholar]
  46. TaheryN. KhodadostM. Jahani SherafatS. C-reactive protein as a possible marker for severity and mortality of COVID-19 infection.Gastroenterol. Hepatol. Bed Bench202114S1S118S12235154611
     [Google Scholar]
  47. TremblayM.E. MadoreC. BordeleauM. TianL. VerkhratskyA. Neuropathobiology of COVID-19: The role for glia.Front. Cell. Neurosci.20201459221410.3389/fncel.2020.59221433304243
     [Google Scholar]
  48. PellegriniL. AlbeckaA. MalleryD.L. SARS-CoV-2 Infects the Brain Choroid Plexus and Disrupts the Blood-CSF Barrier in Human Brain Organoids.Cell Stem Cell2020276951961.e510.1016/j.stem.2020.10.00133113348
     [Google Scholar]
  49. JacobsLG Gourna PaleoudisE Lesky-Di et al. ersistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection.PLoS One20201512e024388210.1371/journal.pone.0243882
     [Google Scholar]
  50. MazzaM.G. De LorenzoR. ConteC. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors.Brain Behav. Immun.20208959460010.1016/j.bbi.2020.07.03732738287
     [Google Scholar]
  51. KormanM. TkachevV. ReisC. COVID-19-mandated social restrictions unveil the impact of social time pressure on sleep and body clock.Sci. Rep.20201012222510.1038/s41598‑020‑79299‑733335241
     [Google Scholar]
  52. VaiB. CazzettaS. GhiglinoD. Risk perception and media in shaping protective behaviors: Insights from the early phase of COVID-19 Italian outbreak.Front. Psychol.20201156342610.3389/fpsyg.2020.56342633250809
     [Google Scholar]
  53. TroyerE.A. KohnJ.N. HongS. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms.Brain Behav. Immun.202087343910.1016/j.bbi.2020.04.02732298803
     [Google Scholar]
  54. CarvalhoP.M.M. MoreiraM.M. de OliveiraM.N.A. LandimJ.M.M. NetoM.L.R. The psychiatric impact of the novel coronavirus outbreak.Psychiatry Res.202028611290210.1016/j.psychres.2020.11290232146248
     [Google Scholar]
  55. CalciaM.A. BonsallD.R. BloomfieldP.S. SelvarajS. BarichelloT. HowesO.D. Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness.Psychopharmacology201623391637165010.1007/s00213‑016‑4218‑926847047
     [Google Scholar]
  56. DaneseA. MoffittT.E. HarringtonH. Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers.Arch. Pediatr. Adolesc. Med.2009163121135114310.1001/archpediatrics.2009.21419996051
     [Google Scholar]
  57. MakI.W.C. ChuC.M. PanP.C. YiuM.G.C. ChanV.L. Long-term psychiatric morbidities among SARS survivors.Gen. Hosp. Psychiatry200931431832610.1016/j.genhosppsych.2009.03.00119555791
     [Google Scholar]
  58. LiuK. ChenY. WuD. LinR. WangZ. PanL. Effects of progressive muscle relaxation on anxiety and sleep quality in patients with COVID-19.Complement. Ther. Clin. Pract.20203910113210.1016/j.ctcp.2020.10113232379667
     [Google Scholar]
  59. SantabárbaraJ. LasherasI. LipnickiD.M. Prevalence of anxiety in the COVID-19 pandemic: An updated meta-analysis of community-based studies.Prog. Neuropsychopharmacol. Biol. Psychiatry202110911020710.1016/j.pnpbp.2020.11020733338558
     [Google Scholar]
  60. ZhuS. GaoQ. YangL. Prevalence and risk factors of disability and anxiety in a retrospective cohort of 432 survivors of Coronavirus disease-2019 (COVID-19) from China.PLoS One20201512e024388310.1371/journal.pone.024388333332386
     [Google Scholar]
  61. DaiL.L. WangX. JiangT.C. LiP.F. WangY. WuS.J. Anxiety and depressive symptoms among COVID-19 patients in Jianghan Fangcang Shelter Hospital in Wuhan, China.PLoS One158e023841610.1371/journal.pone.0238416
     [Google Scholar]
  62. XuZ. ZhangD. XuD. LiX. XieY.J. SunW. Loneliness, depression, anxiety, and post-traumatic stress disorder among Chinese adults during COVID-19: A cross-sectional online survey.PLoS One20211610e025901210.1371/journal.pone.0259012
     [Google Scholar]
  63. dos SantosA.C. TenorioP.J. BarbosaE.A.S. SouzaG.F de A. SouzaG.A. PracianoG de AF. The testing for COVID-19 in symptomatic patients as a protective factor against stress, anxiety, and depression.Rev. Bras. Saúde Mater. Infant.202121s1133143
     [Google Scholar]
  64. MagdyR. ElmaznyA. SolimanS.H. Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case–control study.J. Headache Pain202223110110.1186/s10194‑022‑01468‑y35962348
     [Google Scholar]
  65. LiuZ. QiaoD. XuY. The efficacy of computerized cognitive behavioral therapy for depressive and anxiety symptoms in patients with COVID-19: Randomized controlled trial.J. Med. Internet Res.2021235e2688310.2196/2688333900931
     [Google Scholar]
  66. GuimarãesT.T. SantosH.M.B. SanctosR.T.M. Physical inactivity, chronic diseases, immunity and COVID-19.Rev. Bras. Med. Esporte202026537838110.1590/1517‑8692202026052019_0040
     [Google Scholar]
  67. DongF. LiuH. DaiN. YangM. LiuJ. A living systematic review of the psychological problems in people suffering from COVID-19.J. Affect. Disord.202129217218810.1016/j.jad.2021.05.06034126309
     [Google Scholar]
  68. SpellmanT. ListonC. Toward circuit mechanisms of pathophysiology in depression.Am. J. Psychiatry2020177538139010.1176/appi.ajp.2020.2003028032354265
     [Google Scholar]
  69. BonadimanCSC PassosVMA MooneyM NaghaviM MeloAPS A carga dos transtornos mentais e decorrentes do uso de substâncias psicoativas no Brasil: Estudo de Carga Global de Doença, 1990 e 2015.Rev Bras Epidemiol20172020 S119120410.1590/1980‑549720170005001628658383
     [Google Scholar]
  70. AlmeidaD.B. MotaS.C.B. MesquitaD.D.S. Honório JúniorJ.E.R. A relação entre marcadores inflamatórios e depressão: uma revisão da literatura.Scire Salutis2020111849710.6008/CBPC2236‑9600.2021.001.0010
     [Google Scholar]
  71. GrolliR.E. MingotiM.E.D. BertolloA.G. Impact of COVID-19 in the mental health in elderly: psychological and biological updates.Mol. Neurobiol.20215851905191610.1007/s12035‑020‑02249‑x33404981
     [Google Scholar]
  72. de FigueiredoC.S. SandreP.C. PortugalL.C.L. COVID-19 pandemic impact on children and adolescents’ mental health: Biological, environmental, and social factors.Prog. Neuropsychopharmacol. Biol. Psychiatry202110611017110.1016/j.pnpbp.2020.11017133186638
     [Google Scholar]
  73. BignardiG. DalmaijerE.S. Anwyl-IrvineA.L. Longitudinal increases in childhood depression symptoms during the COVID-19 lockdown.Arch. Dis. Child.2021106879179710.1136/archdischild‑2020‑32037233298552
     [Google Scholar]
  74. MaY.F. LiW. DengH.B. Prevalence of depression and its association with quality of life in clinically stable patients with COVID-19.J. Affect. Disord.202027514514810.1016/j.jad.2020.06.03332658818
     [Google Scholar]
  75. CaiX. HuX. EkumiI.O. Psychological distress and its correlates among COVID-19 survivors during early convalescence across age groups.Am. J. Geriatr. Psychiatry202028101030103910.1016/j.jagp.2020.07.00332753338
     [Google Scholar]
  76. XuF. WangX. YangY. Depression and insomnia in COVID-19 survivors: a cross-sectional survey from Chinese rehabilitation centers in Anhui province.Sleep Med.20229116116510.1016/j.sleep.2021.02.00233627300
     [Google Scholar]
  77. MazzaM.G. PalladiniM. De LorenzoR. Persistent psychopathology and neurocognitive impairment in COVID-19 survivors: Effect of inflammatory biomarkers at three-month follow-up.Brain Behav. Immun.20219413814710.1016/j.bbi.2021.02.02133639239
     [Google Scholar]
  78. GlosterA.T. LamnisosD. LubenkoJ. Impact of COVID-19 pandemic on mental health: An international study.PLoS One20201512e024480910.1371/journal.pone.0244809
     [Google Scholar]
  79. MullaM.S. DarwazehH.A. Activity and longevity of insect growth regulators against mosquitoes.J. Econ. Entomol.197568679179410.1093/jee/68.6.791432
     [Google Scholar]
  80. JiaR. AylingK. ChalderT. Young people, mental health and COVID-19 infection: the canaries we put in the coal mine.Public Health202018915816110.1016/j.puhe.2020.10.01833249392
     [Google Scholar]
  81. HaoF. TanW. JiangL. Do psychiatric patients experience more psychiatric symptoms during COVID-19 pandemic and lockdown? A case-control study with service and research implications for immunopsychiatry.Brain Behav. Immun.20208710010610.1016/j.bbi.2020.04.06932353518
     [Google Scholar]
  82. WuC. HuX. SongJ. Mental health status and related influencing factors of COVID‐19 survivors in Wuhan, China.Clin. Transl. Med.2020102e5210.1002/ctm2.5232508037
     [Google Scholar]
/content/journals/cnsnddt/10.2174/1871527322666230210100048
Loading
Impact of COVID-19 on Anxiety and Depression - Biopsychosocial Factors
CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders) 23, 122 (2024); https://doi.org/10.2174/1871527322666230210100048
/content/journals/cnsnddt/10.2174/1871527322666230210100048
/content/journals/cnsnddt/10.2174/1871527322666230210100048
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): anxiety; biopsychosocial; COVID-19; depression; factors; neuroinflammation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test